CARL ZEISS MEDITEC AG - BR (AFX.DE) Stock Fundamental Analysis
FRA:AFX • DE0005313704
26.86 EUR
-0.14 (-0.52%)
Last: Feb 18, 2026, 03:21 PM
AFX gets a fundamental rating of 5 out of 10. The analysis compared the fundamentals against 67 industry peers in the Health Care Equipment & Supplies industry. Both the profitability and the financial health of AFX get a neutral evaluation. Nothing too spectacular is happening here. AFX may be a bit undervalued, certainly considering the very reasonable score on growth
1. Profitability
1.1 Basic Checks
- In the past year AFX was profitable.
- AFX had a positive operating cash flow in the past year.
- In the past 5 years AFX has always been profitable.
- In the past 5 years AFX always reported a positive cash flow from operatings.
1.2 Ratios
- AFX has a Return On Assets of 4.15%. This is in the better half of the industry: AFX outperforms 61.19% of its industry peers.
- With a Return On Equity value of 6.67%, AFX perfoms like the industry average, outperforming 47.76% of the companies in the same industry.
- AFX has a Return On Invested Capital (5.79%) which is in line with its industry peers.
- The Average Return On Invested Capital over the past 3 years for AFX is below the industry average of 9.66%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 4.15% | ||
| ROE | 6.67% | ||
| ROIC | 5.79% |
ROA(3y)6.33%
ROA(5y)7.85%
ROE(3y)9.62%
ROE(5y)11.54%
ROIC(3y)7.11%
ROIC(5y)9.66%
1.3 Margins
- AFX has a Profit Margin of 6.34%. This is comparable to the rest of the industry: AFX outperforms 52.24% of its industry peers.
- AFX's Profit Margin has declined in the last couple of years.
- The Operating Margin of AFX (10.03%) is comparable to the rest of the industry.
- In the last couple of years the Operating Margin of AFX has declined.
- AFX has a Gross Margin (52.76%) which is comparable to the rest of the industry.
- In the last couple of years the Gross Margin of AFX has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 10.03% | ||
| PM (TTM) | 6.34% | ||
| GM | 52.76% |
OM growth 3Y-21.67%
OM growth 5Y-5.49%
PM growth 3Y-25.69%
PM growth 5Y-7.11%
GM growth 3Y-3.8%
GM growth 5Y-1.12%
2. Health
2.1 Basic Checks
- AFX has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
- Compared to 1 year ago, AFX has about the same amount of shares outstanding.
- The number of shares outstanding for AFX has been reduced compared to 5 years ago.
- Compared to 1 year ago, AFX has an improved debt to assets ratio.
2.2 Solvency
- An Altman-Z score of 2.90 indicates that AFX is not a great score, but indicates only limited risk for bankruptcy at the moment.
- AFX has a Altman-Z score (2.90) which is in line with its industry peers.
- The Debt to FCF ratio of AFX is 4.41, which is a neutral value as it means it would take AFX, 4.41 years of fcf income to pay off all of its debts.
- AFX's Debt to FCF ratio of 4.41 is in line compared to the rest of the industry. AFX outperforms 56.72% of its industry peers.
- A Debt/Equity ratio of 0.27 indicates that AFX is not too dependend on debt financing.
- The Debt to Equity ratio of AFX (0.27) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.27 | ||
| Debt/FCF | 4.41 | ||
| Altman-Z | 2.9 |
ROIC/WACC0.86
WACC6.71%
2.3 Liquidity
- AFX has a Current Ratio of 2.35. This indicates that AFX is financially healthy and has no problem in meeting its short term obligations.
- AFX has a better Current ratio (2.35) than 67.16% of its industry peers.
- AFX has a Quick Ratio of 1.44. This is a normal value and indicates that AFX is financially healthy and should not expect problems in meeting its short term obligations.
- AFX has a better Quick ratio (1.44) than 70.15% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.35 | ||
| Quick Ratio | 1.44 |
3. Growth
3.1 Past
- AFX shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -19.90%.
- Measured over the past 5 years, AFX shows a small growth in Earnings Per Share. The EPS has been growing by 3.28% on average per year.
- Looking at the last year, AFX shows a small growth in Revenue. The Revenue has grown by 7.82% in the last year.
- AFX shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 10.78% yearly.
EPS 1Y (TTM)-19.9%
EPS 3Y-21.2%
EPS 5Y3.28%
EPS Q2Q%N/A
Revenue 1Y (TTM)7.82%
Revenue growth 3Y5.39%
Revenue growth 5Y10.78%
Sales Q2Q%-4.79%
3.2 Future
- Based on estimates for the next years, AFX will show a quite strong growth in Earnings Per Share. The EPS will grow by 16.66% on average per year.
- AFX is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 4.97% yearly.
EPS Next Y20.35%
EPS Next 2Y21.07%
EPS Next 3Y21.31%
EPS Next 5Y16.66%
Revenue Next Year4.23%
Revenue Next 2Y5.18%
Revenue Next 3Y5.72%
Revenue Next 5Y4.97%
3.3 Evolution
- The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
- The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
- Based on the Price/Earnings ratio of 16.68, the valuation of AFX can be described as correct.
- Compared to the rest of the industry, the Price/Earnings ratio of AFX indicates a rather cheap valuation: AFX is cheaper than 85.07% of the companies listed in the same industry.
- Compared to an average S&P500 Price/Earnings ratio of 27.16, AFX is valued a bit cheaper.
- AFX is valuated reasonably with a Price/Forward Earnings ratio of 11.38.
- AFX's Price/Forward Earnings ratio is rather cheap when compared to the industry. AFX is cheaper than 83.58% of the companies in the same industry.
- The average S&P500 Price/Forward Earnings ratio is at 28.10. AFX is valued rather cheaply when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 16.68 | ||
| Fwd PE | 11.38 |
4.2 Price Multiples
- 85.07% of the companies in the same industry are more expensive than AFX, based on the Enterprise Value to EBITDA ratio.
- 82.09% of the companies in the same industry are more expensive than AFX, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 18.03 | ||
| EV/EBITDA | 8.37 |
4.3 Compensation for Growth
- The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
- A more expensive valuation may be justified as AFX's earnings are expected to grow with 21.31% in the coming years.
PEG (NY)0.82
PEG (5Y)5.08
EPS Next 2Y21.07%
EPS Next 3Y21.31%
5. Dividend
5.1 Amount
- With a Yearly Dividend Yield of 2.16%, AFX has a reasonable but not impressive dividend return.
- In the last 3 months the price of AFX has falen by -37.73%. A price decline artificially increases the dividend yield. It may be a sign investors do not expect the dividend to last.
- AFX's Dividend Yield is a higher than the industry average which is at 1.14.
- AFX's Dividend Yield is comparable with the S&P500 average which is at 1.82.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 2.16% |
5.2 History
- The dividend of AFX decreases each year by -1.59%.
Dividend Growth(5Y)-1.59%
Div Incr Years1
Div Non Decr Years4
5.3 Sustainability
- AFX pays out 37.19% of its income as dividend. This is a sustainable payout ratio.
DP37.19%
EPS Next 2Y21.07%
EPS Next 3Y21.31%
FRA:AFX (2/18/2026, 3:21:07 PM)
26.86
-0.14 (-0.52%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)02-12 2026-02-12
Earnings (Next)05-11 2026-05-11
Inst Owners25.21%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap2.40B
Revenue(TTM)2.23B
Net Income(TTM)141.22M
Analysts66.96
Price Target41.46 (54.36%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 2.16% |
Yearly Dividend0.6
Dividend Growth(5Y)-1.59%
DP37.19%
Div Incr Years1
Div Non Decr Years4
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-21.46%
Min EPS beat(2)-33.88%
Max EPS beat(2)-9.05%
EPS beat(4)1
Avg EPS beat(4)-16.59%
Min EPS beat(4)-36.67%
Max EPS beat(4)13.25%
EPS beat(8)4
Avg EPS beat(8)-3.62%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)0.89%
Min Revenue beat(2)-1.14%
Max Revenue beat(2)2.92%
Revenue beat(4)3
Avg Revenue beat(4)1.59%
Min Revenue beat(4)-1.14%
Max Revenue beat(4)3.76%
Revenue beat(8)5
Avg Revenue beat(8)-0.32%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-18.94%
PT rev (3m)-25.37%
EPS NQ rev (1m)-30.35%
EPS NQ rev (3m)N/A
EPS NY rev (1m)-3.32%
EPS NY rev (3m)-6.39%
Revenue NQ rev (1m)-0.03%
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.69%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 16.68 | ||
| Fwd PE | 11.38 | ||
| P/S | 1.08 | ||
| P/FCF | 18.03 | ||
| P/OCF | 11.45 | ||
| P/B | 1.14 | ||
| P/tB | 4.96 | ||
| EV/EBITDA | 8.37 |
EPS(TTM)1.61
EY5.99%
EPS(NY)2.36
Fwd EY8.79%
FCF(TTM)1.49
FCFY5.55%
OCF(TTM)2.35
OCFY8.74%
SpS24.91
BVpS23.66
TBVpS5.41
PEG (NY)0.82
PEG (5Y)5.08
Graham Number29.28
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 4.15% | ||
| ROE | 6.67% | ||
| ROCE | 7.81% | ||
| ROIC | 5.79% | ||
| ROICexc | 5.89% | ||
| ROICexgc | 14.08% | ||
| OM | 10.03% | ||
| PM (TTM) | 6.34% | ||
| GM | 52.76% | ||
| FCFM | 5.98% |
ROA(3y)6.33%
ROA(5y)7.85%
ROE(3y)9.62%
ROE(5y)11.54%
ROIC(3y)7.11%
ROIC(5y)9.66%
ROICexc(3y)7.22%
ROICexc(5y)9.75%
ROICexgc(3y)13.97%
ROICexgc(5y)15.82%
ROCE(3y)9.59%
ROCE(5y)13.04%
ROICexgc growth 3Y-8.4%
ROICexgc growth 5Y5.55%
ROICexc growth 3Y-23.03%
ROICexc growth 5Y-5.34%
OM growth 3Y-21.67%
OM growth 5Y-5.49%
PM growth 3Y-25.69%
PM growth 5Y-7.11%
GM growth 3Y-3.8%
GM growth 5Y-1.12%
F-Score6
Asset Turnover0.65
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.27 | ||
| Debt/FCF | 4.41 | ||
| Debt/EBITDA | 1.61 | ||
| Cap/Depr | 60.61% | ||
| Cap/Sales | 3.44% | ||
| Interest Coverage | 10.38 | ||
| Cash Conversion | 60% | ||
| Profit Quality | 94.37% | ||
| Current Ratio | 2.35 | ||
| Quick Ratio | 1.44 | ||
| Altman-Z | 2.9 |
F-Score6
WACC6.71%
ROIC/WACC0.86
Cap/Depr(3y)109.66%
Cap/Depr(5y)110.76%
Cap/Sales(3y)5.42%
Cap/Sales(5y)4.92%
Profit Quality(3y)64.92%
Profit Quality(5y)71.29%
High Growth Momentum
Growth
EPS 1Y (TTM)-19.9%
EPS 3Y-21.2%
EPS 5Y3.28%
EPS Q2Q%N/A
EPS Next Y20.35%
EPS Next 2Y21.07%
EPS Next 3Y21.31%
EPS Next 5Y16.66%
Revenue 1Y (TTM)7.82%
Revenue growth 3Y5.39%
Revenue growth 5Y10.78%
Sales Q2Q%-4.79%
Revenue Next Year4.23%
Revenue Next 2Y5.18%
Revenue Next 3Y5.72%
Revenue Next 5Y4.97%
EBIT growth 1Y14.86%
EBIT growth 3Y-17.44%
EBIT growth 5Y4.69%
EBIT Next Year66.85%
EBIT Next 3Y28.21%
EBIT Next 5Y16.12%
FCF growth 1Y40.11%
FCF growth 3Y7.85%
FCF growth 5Y-0.04%
OCF growth 1Y-15.15%
OCF growth 3Y3.7%
OCF growth 5Y3.29%
CARL ZEISS MEDITEC AG - BR / AFX.DE FAQ
What is the fundamental rating for AFX stock?
ChartMill assigns a fundamental rating of 5 / 10 to AFX.DE.
What is the valuation status of CARL ZEISS MEDITEC AG - BR (AFX.DE) stock?
ChartMill assigns a valuation rating of 8 / 10 to CARL ZEISS MEDITEC AG - BR (AFX.DE). This can be considered as Undervalued.
Can you provide the profitability details for CARL ZEISS MEDITEC AG - BR?
CARL ZEISS MEDITEC AG - BR (AFX.DE) has a profitability rating of 4 / 10.
What are the PE and PB ratios of CARL ZEISS MEDITEC AG - BR (AFX.DE) stock?
The Price/Earnings (PE) ratio for CARL ZEISS MEDITEC AG - BR (AFX.DE) is 16.68 and the Price/Book (PB) ratio is 1.14.
Is the dividend of CARL ZEISS MEDITEC AG - BR sustainable?
The dividend rating of CARL ZEISS MEDITEC AG - BR (AFX.DE) is 4 / 10 and the dividend payout ratio is 37.19%.